NCT05861271View on ClinicalTrials.gov

Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

1,008

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2028

Conditions
Breast Cancer Stage I
Interventions
DRUG

Capecitabine，Pyrotinib

Pyrotinib and Capecitabine for half a year

Trial Locations (1)

200032

RECRUITING

Breast cancer institute of Fudan University Cancer Hospital, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER